) recently announced positive results from a phase II study on
its S1P1 modulator, ponesimod. Actelion is evaluating ponesimod
as a treatment for patients suffering from moderate-to-severe
chronic plaque psoriasis.
The study achieved its primary objective of improving at least
75% in Psoriasis Area and Severity Index (PASI) from baseline
(PASI75) after 16 weeks. The study enrolled 326 patients. Results
from the study showed that both doses of ponesimod (20 mg and 40
mg) achieved statistical significance.
Around 46% of patients treated with ponesimod (20 mg) showed
an improvement of at least 75% in PASI, whereas 48.1% treated
with ponesimod (40 mg) showed the same at the 16
week. Approximately 13% of patients under placebo showed an
improvement of at least 75 % in PASI after the same duration of
Actelion now plans to initiate a phase III study on ponesimod
in the psoriasis indication. Actelion will be discussing the
phase III study details with health authorities around the world
once full data analysis of the phase II results are done.
We remind investors that in July 2011, Actelion successfully
completed a phase IIb dose-finding study with ponesimod for the
treatment of patients suffering from multiple sclerosis.
We note already approved drugs for the treatment of
moderate-to-severe plaque psoriasis include
Johnson & Johnson
) Humira and
Actelion carries a Zacks #3 Rank (Hold) in the short run.
Johnson & Johnson carries a Zacks #2 Rank (Buy) whereas Amgen
carries a Zacks #1 Rank (Strong Buy).
ABBOTT LABS (ABT): Free Stock Analysis Report
(ALIOF): ETF Research Reports
AMGEN INC (AMGN): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis
PFIZER INC (PFE): Free Stock Analysis Report
To read this article on Zacks.com click here.